Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Corvus Pharmaceuticals (CRVS) Equity Average (2022 - 2025)

Corvus Pharmaceuticals has reported Equity Average over the past 4 years, most recently at $76.0 million for Q3 2025.

  • Quarterly results put Equity Average at $76.0 million for Q3 2025, up 138.86% from a year ago — trailing twelve months through Sep 2025 was $76.0 million (up 138.86% YoY), and the annual figure for FY2024 was $35.6 million, down 24.84%.
  • Equity Average for Q3 2025 was $76.0 million at Corvus Pharmaceuticals, up from $64.8 million in the prior quarter.
  • Over the last five years, Equity Average for CRVS hit a ceiling of $85.1 million in Q2 2022 and a floor of $22.5 million in Q4 2024.
  • Median Equity Average over the past 4 years was $48.0 million (2023), compared with a mean of $51.6 million.
  • Biggest five-year swings in Equity Average: crashed 45.79% in 2024 and later soared 138.86% in 2025.
  • Corvus Pharmaceuticals' Equity Average stood at $60.4 million in 2022, then tumbled by 31.31% to $41.5 million in 2023, then crashed by 45.79% to $22.5 million in 2024, then skyrocketed by 237.94% to $76.0 million in 2025.
  • The last three reported values for Equity Average were $76.0 million (Q3 2025), $64.8 million (Q2 2025), and $40.9 million (Q1 2025) per Business Quant data.